Compare Enveric Biosciences Inc (ENVB) vs WD 40 Company (WDFC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Enveric Biosciences Inc vs WD 40 Company — how do they compare? Enveric Biosciences Inc trades at $1.37 (market cap $5.32M), while WD 40 Company trades at $254.9 (market cap $3.35B). The key difference: WD 40 Company is far larger — about 629.7× Enveric Biosciences Inc's market cap, and WD 40 Company pays a 1.64% dividend while Enveric Biosciences Inc pays none. Which is the better fit depends on your goals.
| ENVB | WDFC | |
|---|---|---|
Market Cap | $5.32M | $3.35B |
Sector | Health | Technology |
52-Week High | $17.40 | $264.91 |
52-Week Low | $1.28 | $187.52 |
Enterprise Value | $408.82K | $3.40B |
Dividend Yield | — | 1.64% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ENVB trades at $1.38, up 4.55% today, with a bearish technical signal from moving averages but neutral oscillators. The company reported a net loss of $8.77M for 2025, though it beat EPS estimates in all four quarters. Recent news highlights participation in investor conferences and progress with its neuroplastogen candidate EB-003, including IND-enabling studies and positive preclinical results.
Outlook hinges on clinical progress, with 75% analyst buy ratings supporting potential upside, but high financial losses and negative ROE/ROA pose significant risks. Investors face volatility from regulatory developments and funding needs, making it speculative despite positive sentiment from recent operational updates.
WDFC trades at $257.99, up 3.56% with strong technical momentum showing bullish signals across moving averages and oscillators. The company delivered impressive Q2 2026 earnings of $2.33 per share, beating estimates by 47%, while maintaining solid profitability with 13.22% net margins. Recent news highlights WD-40's brand strength and consistent performance, with the stock appearing on Zacks' Strong Buy list on July 15, 2026.
The outlook remains positive given strong earnings momentum and brand dominance, though elevated valuation metrics (P/E 37.88) and margin pressure from rising costs present risks. Analyst consensus leans neutral with 71% hold ratings, suggesting cautious optimism about the company's steady growth trajectory amid competitive and inflationary challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Enveric Biosciences Inc
Enveric Biosciences is a biotechnology company focused on developing next-generation psychedelic-inspired therapies for mental health and neuropsychiatric disorders.
Read more on ENVB →About WD 40 Company
WD-40 Company is a global marketing organization dedicated to creating 'positive lasting memories' by developing and selling products that solve maintenance and cleaning problems. Built around the legendary WD-40 Multi-Use Product, the company operates an asset-light business model, focusing on brand management and innovation while utilizing a network of contract manufacturers to deliver solutions across the Americas, EIMEA, and Asia-Pacific.
Read more on WDFC →
